Luis A Brito
Overview
Explore the profile of Luis A Brito including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
2424
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Shah R, Hassett K, Brito L
Methods Mol Biol
. 2016 Oct;
1494:1-13.
PMID: 27718182
Adjuvants are included in sub-unit or recombinant vaccines to enhance the potency of poorly immunogenic antigens. Adjuvant discovery is as complex as it is a multidiscplinary intersection of formulation science,...
12.
Hekele A, Bertholet S, Archer J, Gibson D, Palladino G, Brito L, et al.
Emerg Microbes Infect
. 2015 Jun;
2(8):e52.
PMID: 26038486
The timing of vaccine availability is essential for an effective response to pandemic influenza. In 2009, vaccine became available after the disease peak, and this has motivated the development of...
13.
Brito L, Kommareddy S, Maione D, Uematsu Y, Giovani C, Scorza F, et al.
Adv Genet
. 2015 Jan;
89:179-233.
PMID: 25620012
This chapter provides a brief introduction to nucleic acid-based vaccines and recent research in developing self-amplifying mRNA vaccines. These vaccines promise the flexibility of plasmid DNA vaccines with enhanced immunogenicity...
14.
Shah R, Dodd S, Schaefer M, Ugozzoli M, Singh M, Otten G, et al.
J Pharm Sci
. 2015 Jan;
104(4):1352-61.
PMID: 25600347
Microfluidization is an established technique for preparing emulsion adjuvant formulations for use in vaccines. Although this technique reproducibly yields high-quality stable emulsions, it is complex, expensive, and requires proprietary equipment....
15.
Shah R, OHagan D, Amiji M, Brito L
Nanomedicine (Lond)
. 2014 Dec;
9(17):2671-81.
PMID: 25529570
Particulate adjuvants have been successful at inducing increased immune responses against many poorly immunogenic antigens. However, the mechanism of action of these adjuvants often remains unclear. As more potential vaccine...
16.
Wu T, Singh M, Miller A, De Gregorio E, Doro F, DOro U, et al.
Sci Transl Med
. 2014 Nov;
6(263):263ra160.
PMID: 25411473
Adjuvants increase vaccine potency largely by activating innate immunity and promoting inflammation. Limiting the side effects of this inflammation is a major hurdle for adjuvant use in vaccines for humans....
17.
Bogers W, Oostermeijer H, Mooij P, Koopman G, Verschoor E, Davis D, et al.
J Infect Dis
. 2014 Sep;
211(6):947-55.
PMID: 25234719
Self-amplifying messenger RNA (mRNA) of positive-strand RNA viruses are effective vectors for in situ expression of vaccine antigens and have potential as a new vaccine technology platform well suited for...
18.
Brito L, Chan M, Shaw C, Hekele A, Carsillo T, Schaefer M, et al.
Mol Ther
. 2014 Jul;
22(12):2118-2129.
PMID: 25027661
Nucleic acid-based vaccines such as viral vectors, plasmid DNA, and mRNA are being developed as a means to address a number of unmet medical needs that current vaccine technologies have...
19.
Brito L, OHagan D
J Control Release
. 2014 Jul;
190:563-79.
PMID: 24998942
Vaccine adjuvants interact with the immune system, to increase the potency of vaccine antigens. Many of the adjuvants currently available were developed with little understanding of how they worked. Highly...
20.
Deering R, Kommareddy S, Ulmer J, Brito L, Geall A
Expert Opin Drug Deliv
. 2014 Mar;
11(6):885-99.
PMID: 24665982
Introduction: Nucleic acid-based vaccines are being developed as a means to combine the positive attributes of both live-attenuated and subunit vaccines. Viral vectors and plasmid DNA vaccines have been extensively...